The drug is used only intravenously aftere complete dissolution in 20 ml of water for injection.
The recommended rate of administration is -100 IU / min.
Preparation of the solution: Aghemil B must be diluted only in sterile water for injection. Before breeding vial with drug and sterile water for injections should be brought to a temperature of 20-30 ° C. Sterile disposable needle and syringe to collect the required volume of sterile water for injection (20 ml) and insert it into the vial with the drug. For complete dissolution, gently shake the bottle, not shaking. After 3-5 minutes, a clear or slightly opalescent solution should be obtained. Dilute the drug for 1 hour after preparation. In education gel or clot in a vial the resulting solution can not be used.
The dose of Agamphil B to restore hemostasis is selected individually, depending on the degree of bleeding and the required level of factor IX in blood plasma.The following formula can be recommended for dose calculation:
Required dose = necessary increase in activity. IX (%) × body weight (kg) / 1 (% / IU / kg)
To achieve a satisfactory clinical result, it is necessary to correlate the therapeutic effect with the data of measurements of the level of factor IX in the patient's blood plasma. The required dose of the drug for a single administration and the duration of treatment depends on the severity of factor IX deficiency, as well as the location and volume of bleeding and the clinical condition of the patient.
Light bleeding. For treatment of superficial or beginning bleeding within 2-3 days, a dose of Aghemfil B is introduced, which allows maintaining the concentration of factor IX in blood plasma at 30%.
Moderate bleeding. For the treatment of moderate bleeding, the level of factor IX should be raised to 30-50% by administration of Aghemil B within 3-4 days at intervals of 12-14 hours.
Severe haemorrhage. In patients with life-threatening bleeding or bleeding to vital organs (central nervous system, zygopharyngeal or retroperitoneal space, ilio-lumbar muscle), the level of factor IX in blood plasma should be increased to 80-100% by administration of Aghemil B within 10-14 days with intervals of 12-14 hours.
Surgery. The intensity of the replacement therapy with Agymphil B depends on the type of surgical operation and the subsequent postoperative regimen. With extensive surgical interventions, the level of factor IX should be maintained at a level of at least 50%. For this purpose, transfusions of Agymphil B can be repeated every 6-12 hours for 10-14 days.
Prevention. The scheme preventive treatment should be adjusted in accordance with the individual needs of the patient. Usually, for maintenance therapy in patients with severe hemophilia is a dose of 20-30 IU / kg of Agymphil B, administered 3 times a week in order to maintain 3-5% of the level of factor IX in blood plasma.